Druckenmiller-Backed Rhythm Pharmaceuticals Targets Rare Genetic Obesity Niches

Eli Lilly and Novo Nordisk dominate the weight-loss market with blockbusters like Wegovy and Zepbound, but these therapies address common obesity. Rhythm Pharmaceuticals (NASDAQ: RYTM) focuses on a distinct, underserved segment: rare forms of obesity driven by genetic defects or hypothalamic damage.

This specialized niche has drawn notable institutional interest. In the second quarter, Stanley Druckenmiller’s Duquesne Family Office initiated a position in Rhythm, signaling confidence in the biotech’s trajectory.

Targeting a Specialized Market

Rhythm’s sole commercial product, Imcivree, initially secured U.S. approval in 2020 for chronic weight management in patients with specific protein deficiencies, such as proopiomelanocortin (POMC) deficiency. These conditions disrupt appetite regulation, leading to insatiable hunger and weight gain. Imcivree addresses this mechanism directly. Subsequent approvals extended to Bardet-Biedl syndrome in 2022, though the combined addressable population in the U.S. and Europe was estimated at just 7,500 patients.

A significant expansion arrived in March with approval for acquired hypothalamic obesity (HO), a condition resulting from damage to the brain’s hunger centers. This indication broadens the addressable market to an estimated 25,000–28,000 patients across the U.S., Europe, and Japan—more than quadrupling the prior opportunity. While revenue remains modest, growth is accelerating; second-quarter sales reached $71.3 million, a 47% year-over-year increase.

Assessing the Investment Case

The next potential catalyst is Prader-Willi syndrome, a rare genetic disorder characterized by hyperphagia. Phase 2 results were positive, and Rhythm estimates a U.S. population of 20,000 and roughly 400,000 worldwide. Approval remains years away but would materially enhance the financial outlook. Additionally, the pipeline includes bivamegalon, an oral candidate for acquired HO, offering a needle-free alternative akin to the oral GLP-1 strategies pursued by larger rivals.

Rhythm’s strategy avoids direct competition with pharmaceutical giants, instead dominating narrow indications with high unmet need. This “big fish in a small pond” dynamic supports durable revenue but carries risks: clinical or regulatory setbacks, or new entrants in these limited markets, could disproportionately impact the stock. Notably, the position represents less than 1% of Duquesne’s portfolio, suggesting a measured conviction.

For investors considering exposure, a similar approach warrants consideration: establishing a small starter position with the potential to add upon further clinical and commercial execution.

Source link